SEC Filings

SEC Filings

Email page PDF view Print view Email Alert Social media sharing

SEC Filings

Document Highlights
Other Filings
Filing Description Filing Type Filing Date Event Date  
Proxy DEF 14A 4/27/2017 6/6/2017
Proxy DEFA14A 4/27/2017
8-K 8-K 4/18/2017 4/14/2017
Abstract: 8-K filed by RXi Pharmaceuticals (RXII) covering Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers and Financial Statements and Exhibits.
Proxy PRE 14A 4/12/2017 6/6/2017
8-K 8-K 3/30/2017 3/30/2017
Abstract: 8-K filed by RXi Pharmaceuticals (RXII) covering Results of Operations and Financial Condition and Financial Statements and Exhibits.
10-K 10-K 3/30/2017 12/31/2016
8-K 8-K 3/29/2017 3/29/2017
Abstract: 8-K filed by RXi Pharmaceuticals (RXII) covering Regulation FD Disclosure and Financial Statements and Exhibits.
8-K 8-K 3/28/2017 3/28/2017
Abstract: 8-K filed by RXi Pharmaceuticals (RXII) covering Regulation FD Disclosure and Financial Statements and Exhibits.
13-D SC 13G 2/14/2017
13-D SC 13G 2/14/2017
13-D SC 13G/A 2/13/2017
8-K 8-K 2/3/2017 2/2/2017
Abstract: 8-K filed by RXi Pharmaceuticals (RXII) covering Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
Registration Statement S-8 2/2/2017
Registration Statement S-8 2/2/2017
13-D SC 13G/A 1/12/2017
13-D SC 13G 1/12/2017
8-K 8-K 1/10/2017 1/5/2017
Abstract: 8-K filed by RXi Pharmaceuticals (RXII) covering Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets; Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; and Financial Statements and Exhibits.
13-D SC 13D/A 1/10/2017
8-K 8-K 12/21/2016 12/15/2016
Abstract: On Dec. 21, registrant announced the closing of its underwritten public offering of securities for gross proceeds of $11.5 million, which includes the full exercise of the underwriters’ over-allotment option to purchase additional shares and warrants. Registrant reported the results of its annual meeting of stockholders held Dec. 15. The certificate of designation was included by exhibit.
8-K 8-K 12/19/2016 12/15/2016
Abstract: On Dec. 16, registrant announced the pricing of an underwritten public offering of securities for gross proceeds of $10 million, prior to deducting underwriting discounts, commissions and offering expenses payable by the registrant. The underwriting agreement was included by exhibit.

Displaying 1 to 20 (of 152 filings)